Related Experiment Video
Updated: Jul 8, 2026

In vivo Characterization of Endocrine Disrupting Chemical Effects via Thyroid Hormone Action Indicator Mouse
Published on: October 6, 2023
[Subclinical hyperthyroidism]
Robert Krysiak1, Bogdan Marek, Bogusław Okopień
1Klinika Chorób Wewnetrznych i Farmakologii Klinicznej Katedry Farmakologii, Slaski Uniwersytet Medyczny, Katowice. r.krysiak@poczta.onet.pl
Abstract:
Subclinical hyperthyroidism is a term used to define a clinical condition in which a reduced serum thyroid stimulating hormone (TSH) level is accompanied by thyroxine and tri-iodothyronine levels within the reference ranges. It is a common condition with the prevalence in the general population estimated on 0.6-16%. Subclinical hypethyroidism may progress to overt hyperthyroidism and is associated with the risk of the development of cardiovascular complications (especially atrial fibrillation), osteoporosis and dementia. Indications for the management of subclinical hyperthyroidism still remain controversial. The aim of this paper is to familiarise the reader with the present state of knowledge on the prevalence, etiopathogenesis, clinical manifestation, diagnosis, potential complications, prognosis and treatment of subclinical hyperthyroidism.
Related Concept Videos
Hyperthyroidism I: Introduction
Hyperthyroidism II: Pathophysiology
Graves Disease II: Pathophysiology
Graves' Disease I: Introduction
Hypothyroidism II: Pathophysiology
Goiter
